GO
Loading...

Enter multiple symbols separated by commas

Search results for "PCYC"

REFINE RESULTS

SEARCH RESULTS

About 4 results. Sort By: Date | Relevance
Abbvie completes $21 billion buyout of Pharmacyclics

NEW YORK- Abbvie has completed its $21 billion buyout of Pharmacyclics. The buyout adds another major revenue producer to Abbvie's portfolio, which already includes the world's top-selling drug, Humira. Pharmacyclics Inc. will become a subsidiary of Abbvie and operate from its Sunnyvale, California headquarters.
Source: The Associated Press
Abbvie specifies breakdown of $21 billion Pharmacyclics deal

NEW YORK- Abbvie Inc. specified the stock and cash breakdown on Thursday of its previously announced $21 billion buyout of Pharmacyclics Inc.. The drugmaker said the mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie...
Source: The Associated Press
Cramer: Merger mania-Buckle up for more!

Jim Cramer is seeing too much of everything in the stock market and economy. What does this mean? More mergers ahead! Find out the next play.
Source: CNBC.com | By: Abigail Stevenson
UPDATE 4-Alexion to bolster rare disease offering with $8.4 bln deal

*Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...
Source: Reuters | By: Vidya L Nathan, Natalie Grover and Bill Berkrot